Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruocco

Showing results (1411-1420 of 1,442) with videos related to

Pageof 145
Sort By:
EFSA Journal. European Food Safety Authority|June 12, 2023
Targeted review of maximum residue levels (MRLs) for azocyclotin and cyhexatin, Giulia Bellisai, Giovanni Bernasconi, et al.
EFSA Journal. European Food Safety Authority|March 20, 2023
Review of the existing maximum residue levels for cypermethrins according to Article 12 of Regulation (EC) No 396/2005, Giulia Bellisai, Giovanni Bernasconi, et al.
EFSA Journal. European Food Safety Authority|March 6, 2023
Targeted review of maximum residue levels (MRLs) for bifenthrin, Giulia Bellisai, Giovanni Bernasconi, et al.
EFSA Journal. European Food Safety Authority|August 25, 2025
Evaluation of confirmatory data following the Article 12 MRL review and modification of the existing maximum residue levels in citrus fruits for imazalil, Sofia Batista Leite, Giulia Bellisai, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Cognitive Dysfunction in the Addictions (CDiA): A Neuron to Neighbourhood Collaborative Research Program on Executive Dysfunction and Functional Outcomes in Outpatients Seeking Treatment for AddictionYuliya S Nikolova, Anthony C Ruocco, Daniel Felsky, et al.
Respiratory Research|December 3, 2022
Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment?Riccardo Nevola, Antonio Russo, Samuel Scuotto, et al.
Frontiers in Psychiatry|June 4, 2025
Cognitive Dysfunction in the Addictions (CDiA): protocol for a neuron-to-neighbourhood collaborative research programYuliya S Nikolova, Anthony C Ruocco, Daniel Felsky, et al.
Arquivos De Neuro-Psiquiatria|April 9, 2013
Natalizumab adverse events are rare in patients with multiple sclerosisYára Dadalti Fragoso, Soniza Vieira Alves-Leon, Walter Oleschko Arruda, et al.
Molecular Plant Pathology|September 3, 2014
The Top 10 oomycete pathogens in molecular plant pathologySophien Kamoun, Oliver Furzer, Jonathan D G Jones, et al.
Neurorehabilitation|July 4, 2016
Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disordersYara Dadalti Fragoso, Tarso Adoni, Soniza Vieira Alves-Leon, et al.
Pageof 145

Showing results (1411-1420 of 1,442) with videos related to

Sort By:
Pageof 145
EFSA Journal. European Food Safety Authority|June 12, 2023
Targeted review of maximum residue levels (MRLs) for azocyclotin and cyhexatin, Giulia Bellisai, Giovanni Bernasconi, et al.
EFSA Journal. European Food Safety Authority|March 20, 2023
Review of the existing maximum residue levels for cypermethrins according to Article 12 of Regulation (EC) No 396/2005, Giulia Bellisai, Giovanni Bernasconi, et al.
EFSA Journal. European Food Safety Authority|March 6, 2023
Targeted review of maximum residue levels (MRLs) for bifenthrin, Giulia Bellisai, Giovanni Bernasconi, et al.
EFSA Journal. European Food Safety Authority|August 25, 2025
Evaluation of confirmatory data following the Article 12 MRL review and modification of the existing maximum residue levels in citrus fruits for imazalil, Sofia Batista Leite, Giulia Bellisai, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2024
Cognitive Dysfunction in the Addictions (CDiA): A Neuron to Neighbourhood Collaborative Research Program on Executive Dysfunction and Functional Outcomes in Outpatients Seeking Treatment for AddictionYuliya S Nikolova, Anthony C Ruocco, Daniel Felsky, et al.
Respiratory Research|December 3, 2022
Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment?Riccardo Nevola, Antonio Russo, Samuel Scuotto, et al.
Frontiers in Psychiatry|June 4, 2025
Cognitive Dysfunction in the Addictions (CDiA): protocol for a neuron-to-neighbourhood collaborative research programYuliya S Nikolova, Anthony C Ruocco, Daniel Felsky, et al.
Arquivos De Neuro-Psiquiatria|April 9, 2013
Natalizumab adverse events are rare in patients with multiple sclerosisYára Dadalti Fragoso, Soniza Vieira Alves-Leon, Walter Oleschko Arruda, et al.
Molecular Plant Pathology|September 3, 2014
The Top 10 oomycete pathogens in molecular plant pathologySophien Kamoun, Oliver Furzer, Jonathan D G Jones, et al.
Neurorehabilitation|July 4, 2016
Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disordersYara Dadalti Fragoso, Tarso Adoni, Soniza Vieira Alves-Leon, et al.
Pageof 145